Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Gonadorelin

GnRH, Luteinizing Hormone-Releasing Hormone, LHRH, Factrel

Quick Stats
Studies 192
Trials 100
Score 3
2025 pubmed

Exposure risks to phthalates by cosmetics and personal care products in pregnant women and early life: Urinary levels, mechanisms, biomarkers, and mitigation strategies: a review.

Eslami. Hadi H; Nemati. Arezoo A; Jamshidi. Mahdieh M; Ghaffarian-Bahraman. Ali A; Askari. Sahar Ghaleh SG; Askari. Foad Ranjbar FR

Key Findings

  • Lipstick, deodorants, and nail polish are major sources of phthalates for pregnant women and infants
  • Phthalate exposure is linked to hormonal disruptions, organ toxicity, and reproductive problems such as premature birth and early puberty
  • Biomarkers like DNA methylation changes, EV‑miRNAs, blood sugar, lipid levels, and MDA can indicate phthalate exposure

Practical Outcomes

  • Choose phthalate‑free or low‑phthalate cosmetics, especially during pregnancy and early childhood. Look for products that use safer alternatives like citrates. If possible, monitor suggested biomarkers (e.g., blood lipids, MDA) to gauge exposure and adjust product choices accordingly.

Summary

This review shows that many everyday cosmetics like lipstick, deodorant, and nail polish can expose pregnant women and babies to harmful chemicals called phthalates, which can mess up hormones, liver, kidney, and even affect birth outcomes. It points out specific biomarkers you can track and suggests swapping phthalates for safer ingredients like citrates to cut down exposure.

Abstract

The increasing use of personal care products (PCPs) and cosmetics have increased the risk of exposure to phthalates, especially in the early stages of life for maternal-fetal-infant. This review aimed to determine the phthalates exposure risk through the consumption of PCPs and cosmetics in Pregnant women and early life, determine the mechanisms, biomarkers, and mitigation strategies for phthalates. The highest phthalates exposure levels of pregnant women (as well as fetal exposure through placenta and infants through breast milk) who used PCPs and cosmetics continuously or in larger quantities, especially lipstick, deodorants, and nail polish, were related to MEP˃ MnBP˃ MEHHP, respectively. The greatest phthalates exposure health risks in early life include hormonal disorders, especially cholesterol, thyroid, estrogen, and androgen, and toxicity to the liver, kidney, and thyroid, skin inflammation and irritation, and reproductive system toxicity, including premature birth and menopause, miscarriage, low birth weight and height, and early puberty. Maternal and placenta hormones disorders, such as gonadotropin-releasing hormone (GnRH) and estrogen, and decreases in steroid hormones such as SHBG (sex-hormone binding globulin) and testosterone, were the main mechanisms for phthalates exposures. Suitable biomarkers for assessing phthalates exposure by PCPs were changes in DNA methylation, placental-derived extracellular vehicles related to microRNAs (EV-miRNAs), maternal glycemia and lipid profiles, and malondialdehyde (MDA) level. Replacing high-risk phthalates with less toxic substances, like citrates, during the PCPs production is a suitable way to lower phthalate exposure. It is recommended that monitoring of phthalates biomarkers in the early years of life in future studies.

Study Information

Provider

pubmed

Year

2025

Date

2025-10-23T00:00:00.000Z

DOI

10.1016/j.cbi.2025.111786

References

68